Get started
Author

Christina To

ORCID: 0000-0001-7164-8072
Observed ORCID: 0000-0001-7164-8072
OpenAlex ID: A5019726727
Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
2023 · Jason R. Westin, Frederick L. Locke, et al. · Clinical Cancer Research · 55
PDF
Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
2023 · Simone Filosto, Saran Vardhanabhuti, et al. · Blood Cancer Discovery · 51
PDF
Axicabtagene ciloleucel vs standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume
2024 · Frederick L. Locke, Olalekan O. Oluwole, et al. · Blood · 31
Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
2024 · Dasom (Caroline) Lee, Swetha Kambhampati, et al. · Blood · 12
PDF
Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11
2023 · Michael D. Jain, David B. Miklos, et al. · Clinical Cancer Research · 8
PDF
An Inflammatory Biomarker Signature Reproducibly Predicts CAR-T Treatment Failure in Patients with Aggressive Lymphoma across the Zuma Trials Cohorts
2023 · Sandeep Raj, Jin Xie, et al. · Blood · 5
Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care (SOC) in Patients with Primary Refractory or Early Relapsed Large B-Cell Lymphoma (LBCL)
2025 · Jason R. Westin, Olalekan O Oluwole, et al. · Transplantation and Cellular Therapy · 1
Data from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
2023 · Jason R. Westin, Frederick L. Locke, et al. · 1
Supplementary Methods S1 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11
2025 · Michael D. Jain, David B. Miklos, et al.
PDF
Supplementary Figure S7 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11
2025 · Michael D. Jain, David B. Miklos, et al.
PDF
Supplementary Table S2 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11
2025 · Michael D. Jain, David B. Miklos, et al.
PDF
Supplementary Figure S6 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11
2025 · Michael D. Jain, David B. Miklos, et al.
PDF
Supplementary Table S1 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11
2025 · Michael D. Jain, David B. Miklos, et al.
PDF
Supplementary Figure S1 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11
2025 · Michael D. Jain, David B. Miklos, et al.
PDF
Supplementary Figure S3 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11
2025 · Michael D. Jain, David B. Miklos, et al.
PDF
Supplementary Figure S2 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11
2025 · Michael D. Jain, David B. Miklos, et al.
PDF
Supplementary Figure S8 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11
2025 · Michael D. Jain, David B. Miklos, et al.
PDF
Supplementary Figure S5 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11
2025 · Michael D. Jain, David B. Miklos, et al.
PDF
Supplementary Figure S4 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11
2025 · Michael D. Jain, David B. Miklos, et al.
PDF
Supplementary Figure S2 from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
2025 · Jason R. Westin, Frederick L. Locke, et al.
PDF
Supplementary Figure S1 from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
2025 · Jason R. Westin, Frederick L. Locke, et al.
PDF
Supplementary Figure S4 from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
2025 · Jason R. Westin, Frederick L. Locke, et al.
PDF
Supplementary Tables S1-S11 from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
2025 · Jason R. Westin, Frederick L. Locke, et al.
PDF
Supplementary Figure S3 from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
2025 · Jason R. Westin, Frederick L. Locke, et al.
PDF
Supplementary Figure S5 from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
2025 · Jason R. Westin, Frederick L. Locke, et al.
PDF
Works count: 105
Citation count: 164
H-index: 5
I10-index: 4
Year
Topic
Type